- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03137160
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Gahanna, Ohio, United States, 43230
- The Ohio State University Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Major inclusion criteria:
- Have a clinical diagnosis of classic Pyoderma Gangrenosum for at least 3 months as determined by the investigator and an external reviewer on the basis of results from clinical, histological and laboratory assessments
At screening, have a Pyoderma Gangrenosum ulcer characterized by 'item a' AND 3/5 features in 'item b' OR 2/5 features in 'item b' with support from one of the conditions listed in c.
a. Stable or increasing size within 2 months preceding screening by patient report or documentation b. Features such as violaceous border, undermining, d. Intralesional corticosteroids within 8 weeks of day 0; topical immunomodulators are permitted.
e. Wound debridement within 2 weeks of Day 0; dressing changes allowed per investigator discretion.
g. Systemic antibiotics within 2 weeks of Day 0 h. Live, attenuated vaccines within 3 months of Day 0; or live, seasonal-flu- or H1N1 vaccines within 2 weeks of Day 0. Note: recombinant- and/or killed vaccines are permitted.
i. Hyperbaric treatment within 4 weeks of Day 0 j. Investigational drug or investigational device within 30 days or 5 half-lives of Day 0, whichever is longer k. Prior exposure to ixekizumab l. Other treatments not described above should be maintained at a stable dose and frequency throughout the study as best as possible 13. Major, general surgery within 3 months of screening, or anticipated general surgery during the study period 14. Pregnancy, plans to become pregnant during the course of the study, delivery within 3 months of screening, or breast-feeding 15. If previous use of cyclosporine or systemic corticosteroids, failure to have any stabilization/response is exclusionary. This potentially indicates the disease is not Pyoderma Gangrenosum.
Exclusion Criteria:
Major exclusion criteria:
- Any condition (e.g., psychiatric illness, severe alcoholism, or drug abuse) or situation that may compromise the ability of the subject to give written informed consent, may put the subject at significant risk, may jeopardize the subject's safety after exposure to the study drug, may confound the study results, or may interfere significantly with the subject's participation in the study
- History of malignancy within 2 years of screening other than carcinoma in situ of the cervix or adequately treated, non-metastatic, squamous or basal cell carcinoma of the skin
- History of seropositivity for HIV antibody; active or carrier status of hepatitis B [surface antigen (HBsAg) positive, or core antibody (anti-HBc) positive with negative surface antibody]; active hepatitis C (i.e. not treated or not cleared spontaneously, as confirmed by HCV PCR)
- History of severe allergic or anaphylactic reaction to monoclonal antibodies
- Systemic infection (excluding wound colonization) requiring oral antibiotics within 2 weeks of Day 0
History of the following treatments:
- Anti-Tumor Necrosis Factor or other biologic therapies within 5 half-lives of screening
- Changes (addition, discontinuation, or changes in dose) in immunosuppressive medication (including cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, apremilast, dapsone, or corticosteroids) within 2 months of Day 0
- Systemic corticosteroids > 20 mg per day (prednisone or prednisone equivalent) within 8 weeks of Day 0, or change in dose within 8 weeks of Day 0. Steroids may be tapered (although not increased above the Day 0 dose) during the trial as determined by the investigator.
they are prescribed at stable doses for two months prior to baseline and are 20 mg or less per day of prednisone or other equivalently-dosed corticosteroids.
4. Intralesional corticosteroids within 4 weeks of screening and during the study are not permitted 5. Other therapies that are non-immunosuppressive and non-investigational can be started or continued at physician discretion provided the medicine has no history of association with progressive multifocal leukoencephalopathy. Antibiotics may be used as needed for evidence of superinfection, positive culture results, malodor, green discharge, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ixekizumab (Taltz)
We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangrenosum .
Therefore, there is only one treatment arm.
The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
|
Injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12
Time Frame: 12 Weeks
|
The primary outcome will be the proportion of subjects achieving a 2-point reduction in the 5-point investigator global assessment for the target ulcer at Week 12. The measure type and unit of measure are the proportion of participants. The IGA utilizes a 5 point Investigator Global Assessment measuring disease severity from 0- clear, 1-minimal, 2-mild, 3-moderate, 4- severe. 4 is the worst |
12 Weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Benjamin Kaffenberger, MD, Dermatologist
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017H0045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pyoderma Gangrenosum
-
SWISS BIOPHARMA MED GmbHCompletedPyoderma | Pyoderma Gangrenosum | Pyoderma Vegetans | Pyoderma Gangrenosum Surrounding Surgical StomaBelarus, Latvia
-
Dartmouth-Hitchcock Medical CenterBristol-Myers SquibbNot yet recruiting
-
Erasmus Medical CenterNot yet recruitingPyoderma Gangrenosum
-
Technical University of MunichNovartisCompletedPyoderma GangrenosumGermany
-
Wright State UniversityWake Forest University Health Sciences; Stanford UniversityWithdrawnPyoderma GangrenosumUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownPyoderma GangrenosumFrance
-
University of ZurichCompleted
-
Icahn School of Medicine at Mount SinaiBoehringer IngelheimRecruiting
-
InflaRx GmbHRecruitingPhase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumPyoderma GangrenosumUnited States, Spain, Australia, France, Germany, Switzerland, Hungary, Italy, Poland
-
AbbVieRecruiting
Clinical Trials on Ixekizumab
-
Shanghai Yueyang Integrated Medicine HospitalShanghai Skin Disease and Venereal Disease HospitalNot yet recruiting
-
Eli Lilly and CompanyCompletedPlaque PsoriasisUnited States, Puerto Rico
-
University of New MexicoCompletedLichen Planus | Lichen Planopilaris | Lichen Planus ScalpUnited States
-
Massachusetts Eye Research and Surgery InstitutionEli Lilly and CompanyRecruitingUveitis, Anterior | Panuveitis | Uveitis, Posterior | Uveitis, IntermediateUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedPsoriatic ArthritisUnited States, France, Taiwan, Spain, Australia, Germany, United Kingdom, Poland, Czechia, Italy
-
Eli Lilly and CompanyCompletedRheumatoid ArthritisGermany, United States, Romania, Russian Federation, Argentina, Peru, Poland, Taiwan, Korea, Republic of, India, Chile
-
Eli Lilly and CompanyCompletedPsoriasisItaly, United States, Australia, Germany, Canada, Denmark, Japan, Poland, Hungary, Romania, United Kingdom
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting